164 related articles for article (PubMed ID: 35098333)
1. Relation between auditory difficulties and bortezomib-induced peripheral neuropathy in multiple myeloma: a single-center cross-sectional study.
Giraudet F; Selvy M; Kerckhove N; Pereira B; Barreau F; Nguyen D; Busserolles J; Cabrespine A; Chaleteix C; Soubrier M; Bay JO; Lemal R; Balayssac D
Eur Arch Otorhinolaryngol; 2022 Apr; 279(4):2197-2201. PubMed ID: 35098333
[TBL] [Abstract][Full Text] [Related]
2. Prevalence of Chemotherapy-Induced Peripheral Neuropathy in Multiple Myeloma Patients and its Impact on Quality of Life: A Single Center Cross-Sectional Study.
Selvy M; Kerckhove N; Pereira B; Barreau F; Nguyen D; Busserolles J; Giraudet F; Cabrespine A; Chaleteix C; Soubrier M; Bay JO; Lemal R; Balayssac D
Front Pharmacol; 2021; 12():637593. PubMed ID: 33967771
[TBL] [Abstract][Full Text] [Related]
3. Chemotherapy-induced neuropathy in multiple myeloma: influence on quality of life and development of a questionnaire to compose common toxicity criteria grading for use in daily clinical practice.
Beijers AJ; Vreugdenhil G; Oerlemans S; Eurelings M; Minnema MC; Eeltink CM; van de Poll-Franse LV; Mols F
Support Care Cancer; 2016 Jun; 24(6):2411-20. PubMed ID: 26634561
[TBL] [Abstract][Full Text] [Related]
4. Duloxetine prevents bortezomib and paclitaxel large-fiber chemotherapy-induced peripheral neuropathy (LF-CIPN) in sprague dawley rats.
Mansooralavi N; Khomula EV; Levine JD
Mol Pain; 2023; 19():17448069231185694. PubMed ID: 37338165
[TBL] [Abstract][Full Text] [Related]
5. Adhesive capsaicin 8% patch for improved control of pain caused by chemotherapy-induced peripheral neuropathy in patients with multiple myeloma: A single-centre, seven-case series.
Moreno-Alonso D; Llorens-Torromé S; Corcoy de Febrer B; Amandi García M; Serrano-Bermúdez G; Trelis-Navarro J; Mayoral-Rojals V; Serrano-Afonso A
J Oncol Pharm Pract; 2024 Jun; 30(4):752-758. PubMed ID: 38415287
[TBL] [Abstract][Full Text] [Related]
6. The magnitude of neurotoxicity in patients with multiple myeloma and the impact of dose modifications: results from the population-based PROFILES registry.
Beijers AJ; Oerlemans S; Mols F; Eurelings M; Minnema MC; Vreugdenhil A; van de Poll-Franse LV
Ann Hematol; 2017 Apr; 96(4):653-663. PubMed ID: 28116479
[TBL] [Abstract][Full Text] [Related]
7. Chemotherapy-induced peripheral neuropathy: evidence from genome-wide association studies and replication within multiple myeloma patients.
Mahmoudpour SH; Bandapalli OR; da Silva Filho MI; Campo C; Hemminki K; Goldschmidt H; Merz M; Försti A
BMC Cancer; 2018 Aug; 18(1):820. PubMed ID: 30111286
[TBL] [Abstract][Full Text] [Related]
8. Chemotherapy-Induced Peripheral Neuropathy Detection via a Smartphone App: Cross-sectional Pilot Study.
Chen CS; Kim J; Garg N; Guntupalli H; Jagsi R; Griggs JJ; Sabel M; Dorsch MP; Callaghan BC; Hertz DL
JMIR Mhealth Uhealth; 2021 Jul; 9(7):e27502. PubMed ID: 36260403
[TBL] [Abstract][Full Text] [Related]
9. Incidence of chemotherapy-induced peripheral neuropathy within 12 weeks of starting neurotoxic chemotherapy for multiple myeloma or lymphoma: a prospective, single-center, observational study.
Ajewole VB; Cox JE; Swan JT; Chikermane SG; Lamoth B; Iso T; Okolo LO; Ford CL; Schneider AM; Hobaugh EC; Baker KR
Support Care Cancer; 2020 Apr; 28(4):1901-1912. PubMed ID: 31359183
[TBL] [Abstract][Full Text] [Related]
10. Mechanisms of peripheral neuropathy associated with bortezomib and vincristine in patients with newly diagnosed multiple myeloma: a prospective analysis of data from the HOVON-65/GMMG-HD4 trial.
Broyl A; Corthals SL; Jongen JL; van der Holt B; Kuiper R; de Knegt Y; van Duin M; el Jarari L; Bertsch U; Lokhorst HM; Durie BG; Goldschmidt H; Sonneveld P
Lancet Oncol; 2010 Nov; 11(11):1057-65. PubMed ID: 20864405
[TBL] [Abstract][Full Text] [Related]
11. Investigation of the frequency of bortezomib neuropathy in patients with multiple myeloma diagnosis with normal and abnormal genetic characteristics.
Kul AN; Ipek Y
J Oncol Pharm Pract; 2023 Oct; 29(7):1652-1660. PubMed ID: 36237141
[TBL] [Abstract][Full Text] [Related]
12. Electronic versus paper-pencil methods for assessing chemotherapy-induced peripheral neuropathy.
Knoerl R; Gray E; Stricker C; Mitchell SA; Kippe K; Smith G; Dudley WN; Lavoie Smith EM
Support Care Cancer; 2017 Nov; 25(11):3437-3446. PubMed ID: 28577231
[TBL] [Abstract][Full Text] [Related]
13. Prevention of Bortezomib-Related Peripheral Neuropathy With Docosahexaenoic Acid and α-Lipoic Acid in Patients With Multiple Myeloma: Preliminary Data.
Maschio M; Zarabla A; Maialetti A; Marchesi F; Giannarelli D; Gumenyuk S; Pisani F; Renzi D; Galiè E; Mengarelli A
Integr Cancer Ther; 2018 Dec; 17(4):1115-1124. PubMed ID: 30295079
[TBL] [Abstract][Full Text] [Related]
14. The prevalence and pattern of chemotherapy-induced peripheral neuropathy among women with breast cancer receiving care in a large community oncology practice.
Simon NB; Danso MA; Alberico TA; Basch E; Bennett AV
Qual Life Res; 2017 Oct; 26(10):2763-2772. PubMed ID: 28664460
[TBL] [Abstract][Full Text] [Related]
15. Impact of Chemotherapy-Induced Peripheral Neuropathy on Quality of Life in Patients with Advanced Lung Cancer Receiving Platinum-Based Chemotherapy.
Hung HW; Liu CY; Chen HF; Chang CC; Chen SC
Int J Environ Res Public Health; 2021 May; 18(11):. PubMed ID: 34073174
[TBL] [Abstract][Full Text] [Related]
16. Statistical identification of predictors for peripheral neuropathy associated with administration of bortezomib, taxanes, oxaliplatin or vincristine using ordered logistic regression analysis.
Kanbayashi Y; Hosokawa T; Okamoto K; Konishi H; Otsuji E; Yoshikawa T; Takagi T; Taniwaki M
Anticancer Drugs; 2010 Oct; 21(9):877-81. PubMed ID: 20679888
[TBL] [Abstract][Full Text] [Related]
17. Reference data of the European Organisation for Research and Treatment of Cancer (EORTC) QLQ-CIPN20 Questionnaire in the general Dutch population.
Mols F; van de Poll-Franse LV; Vreugdenhil G; Beijers AJ; Kieffer JM; Aaronson NK; Husson O
Eur J Cancer; 2016 Dec; 69():28-38. PubMed ID: 27814471
[TBL] [Abstract][Full Text] [Related]
18. [Chemotherapy-induced peripheral neuropathy: Symptomatology and epidemiology].
Kerckhove N; Collin A; Condé S; Chaleteix C; Pezet D; Balayssac D; Guastella V
Bull Cancer; 2018 Nov; 105(11):1020-1032. PubMed ID: 30244980
[TBL] [Abstract][Full Text] [Related]
19. Caspase-Dependent HMGB1 Release from Macrophages Participates in Peripheral Neuropathy Caused by Bortezomib, a Proteasome-Inhibiting Chemotherapeutic Agent, in Mice.
Tsubota M; Miyazaki T; Ikeda Y; Hayashi Y; Aokiba Y; Tomita S; Sekiguchi F; Wang D; Nishibori M; Kawabata A
Cells; 2021 Sep; 10(10):. PubMed ID: 34685531
[TBL] [Abstract][Full Text] [Related]
20. Exploring the impact of a decision support algorithm to improve clinicians' chemotherapy-induced peripheral neuropathy assessment and management practices: a two-phase, longitudinal study.
Knoerl R; Mazzola E; Hong F; Salehi E; McCleary N; Ligibel J; Reyes K; Berry DL
BMC Cancer; 2021 Mar; 21(1):236. PubMed ID: 33676431
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]